Inventor · disambiguated record
Seppo Yla-Herttuala
Also filed as: YLA-HERTTUALA SEPPO · YLAE-HERTTUALA SEPPO · YLÄ-HERTTUALA SEPPO PASI ANTERO · Ylä-Herttuala Seppo
14 granted patents·47 pending applications·70 citations·filing 1999–2024
89Inventor score
Files withTRIZELL LTD12ARK THERAPEUTICS LTD5AIRENNE KARI JUHANI4YLA-HERTTUALA SEPPO4FINVECTOR VISION THERAPIES LTD3
Top patents by PatentIndex Score
61 records- 0184US11261416B2Fixed-bed bioreactor with constant-flow pump / tubing systemTRIZELL LTD·Filed 2017·Granted Mar 1, 2022·2 cites·37 claims
- 0284US11242504B2Aseptic bioreactor sampling systemTRIZELL LTD·Filed 2019·Granted Feb 8, 2022·2 cites·19 claims
- 0382US6958147B1Use of VEGF-C to prevent restenosisLUDWIG INST CANCER RES·Filed 1999·Granted Oct 25, 2005·41 cites·27 claims
- 0475US7393677B2Avidin-pseudotyped viral vectors and their useARK THERAPEUTICS LTD·Filed 2006·Granted Jul 1, 2008·3 cites·7 claims
- 0575US2023235341A1Anti-angiogenic gene therapy with soluble vegf receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinomaTRIZELL LTD·Filed 2022·Application pending·0 cites
- 0674US12116559B2Method of manufacturing a recombinant polypeptideTRIZELL LTD·Filed 2021·Granted Oct 15, 2024·0 cites·6 claims
- 0773US8025886B2Modified VEGF-A with improved angiogenic propertiesVEGENICS PTY LTD·Filed 2006·Granted Sep 27, 2011·2 cites·48 claims
- 0872US10829785B2Nucleic acid application primersTRIZELL LTD·Filed 2019·Granted Nov 10, 2020·0 cites·4 claims
- 0971US2025163519A1Gene therapy vector contamination assayTRIZELL LTD·Filed 2024·Application pending·0 cites
- 1068US7320679B2Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasiaARK THERAPEUTICS LTD·Filed 2003·Granted Jan 22, 2008·1 cites·29 claims
- 1166US2019275106A1Anti-Angiogenic Gene Therapy KitTRIZELL LTD·Filed 2019·Application pending·0 cites
- 1263US2014057851A1Anti-Angiogenic Gene Therapy With Soluble VEGF Receptors -1, -2 and -3 Together With Paclitaxel Prolongs Survival Of Mice With Human Ovarian CarcinomaYLA-HERTTUALA SEPPO·Filed 2013·Application pending·0 cites
- 1359US12152281B2Gene therapy vector contamination assayTRIZELL LTD·Filed 2019·Granted Nov 26, 2024·0 cites·10 claims
- 1459US2010003746A1Production of Lentiviral VectorsLESCH HANNA P·Filed 2008·Application pending·0 cites
- 1558US2014017204A1Transfection of Mesothelium Body Cavity Lining with Gene Agents Followed by Chemotharapy to Treat Cancer of Organs in the Body CavityPARKER NIGEL·Filed 2013·Application pending·0 cites
- 1658US2020101100A1Transgene-Cytotoxic Combination TherapyGLIOTHERAPY LTD·Filed 2019·Application pending·0 cites
- 1758US2014017202A1Transfection of Mesothelium Body Cavity Lining with Gene Agents Followed by Chemotharapy to Treat Cancer of Organs in the Body CavityPARKER NIGEL·Filed 2013·Application pending·0 cites
- 1855US2006093653A1Periadventitial delivery deviceMARTIN JOHN F·Filed 2005·Application pending·0 cites
- 1955US2017016028A1Production of Lentiviral VectorsFINVECTOR VISION THERAPIES LTD·Filed 2016·Application pending·0 cites
- 2054US2008261234A1Peptides and their use in assays for cardiovascular diseaseNARVANEN OUTI·Filed 2007·Application pending·0 cites
- 2154US2010041605A1Use of VEGF-C or VEGF-D in Reconstructive SurgeryVEGENICS LTD·Filed 2009·Application pending·0 cites
- 2254US2023226154A1Compositions and methods for treating cancerTRIZELL LTD·Filed 2021·Application pending·0 cites
- 2353US6579855B1Adenovirus-mediated gene therapyARK THERAPEUTICS LTD·Filed 1999·Granted Jun 17, 2003·19 cites·9 claims
- 2453US2009047733A1Avidin-Pseudotyped Viral Vectors and Their UseAIRENNE KARI JUHANI·Filed 2008·Application pending·0 cites
- 2553US2016097060A1Production of Vectors for Non-Dividing Host CellsFINVECTOR VISION THERAPIES LTD·Filed 2015·Application pending·0 cites
- 2652US8455453B2Use of VEGF-D gene to prevent restenosisALITALO KARI·Filed 2005·Granted Jun 4, 2013·0 cites·46 claims
- 2752US2016058888A1Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and GanciclovirFINVECTOR VISION THERAPIES LTD·Filed 2014·Application pending·0 cites
- 2851US2019276846A1Seeding An Adherent Cell Bioreactor With Non-Adherent Cells Increases Seeding Density Limit And Reduces Required Expansion TimeTRIZELL LTD·Filed 2019·Application pending·0 cites
- 2951US2022186228A1Synthetic microrna mimicsRNATIVES INC·Filed 2019·Application pending·0 cites
- 3050US2004091934A1Peptides and their use in assays for cardiovascular diseaseFiled 2001·Application pending·0 cites
- 3150US2008305999A1Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasiaMARTIN JOHN FRANCIS·Filed 2007·Application pending·0 cites
- 3250US2020222477A1Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive CancerTRIZELL LTD·Filed 2019·Application pending·0 cites
- 3349US2008147045A1Use of VEGF-C or VEGF-D in Reconstructive SurgeryLICENTIA LTD·Filed 2007·Application pending·0 cites
- 3448US2010221791A1Method for Incorporating Proteins Into Lentivirus VectorsSCHENKWEIN DIANA·Filed 2008·Application pending·0 cites
- 3548US2020354409A1Adenoviral Polypeptide IX Increases Adenoviral Gene Therapy Vector Productivity and InfectivityKuopio Center for Gene and Cell Therapy Oy·Filed 2019·Application pending·0 cites
- 3648US2003039694A1Periadventitial delivery deviceFiled 2002·Application pending·0 cites
- 3747US6974816B2Combination for the treatment of endothelial damageLUDWIG INSTITIUTE FOR CANCER R·Filed 2002·Granted Dec 13, 2005·0 cites·7 claims
- 3847US2009176660A1Engineered Baculoviruses and Their UseYLA-HERTTUALA SEPPO·Filed 2008·Application pending·0 cites
- 3947US2011052540A1Non-Aggregating Virus FormulationSHAW ROBERT·Filed 2008·Application pending·0 cites
- 4046US2017051309A1Seeding An Adherent Cell Bioreactor With Non-Adherent Cells Increases Seeding Density Limit And Reduces Required Expansion TimeTRIZELL LTD·Filed 2015·Application pending·0 cites
- 4145US2004248796A1VEGF-B and PDGF modulation of stem cellsFiled 2004·Application pending·0 cites
- 4245US2004146487A1Avidin pseudotyped viral vectors and their useAIRENNE KARI JUHANI·Filed 2002·Application pending·0 cites
- 4344US8188039B2VEGF-D mutants and their useTOIVANEN PYRY·Filed 2008·Granted May 29, 2012·0 cites·8 claims
- 4443US2005201983A1Engineered baculoviruses and their useYLA-HERTTUALA SEPPO·Filed 2003·Application pending·0 cites
- 4543US2012071406A1Modified vegf-a with improved angiogenic propertiesALITALO KARI·Filed 2011·Application pending·0 cites
- 4642US2005043235A1Use of VEGF-C or VEGF-D in reconstructive surgeryFiled 2004·Application pending·0 cites
- 4741US2012308522A1Therapeutic Use of Growth Factor, and Delivery Device, Especially for the Treatment of Intimal HyperplasiaMARTIN JOHN FRANCIS·Filed 2012·Application pending·0 cites
- 4841US2017348345A1Combination Therapy For CancerGLIOTHERAPY LTD·Filed 2017·Application pending·0 cites
- 4940US2013310444A1Combination Therapy for CancerSAMARANAYAKE HARITHA·Filed 2012·Application pending·0 cites
- 5039US7208291B2Nucleic acids encoding biotin-binding receptorsARK THERAPEUTICS LTD·Filed 2003·Granted Apr 24, 2007·0 cites·5 claims
Showing the top 50 of 61 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →